AACR22: Affimed's NK cell therapy produces more patient responses — and more durability questions
NEW ORLEANS — One year after surprising the AACR crowd with solid initial NK cell data, Affimed is back with another cut Sunday.
And while the German biotech tacked on another three complete responses since a November update, questions around durability will potentially start to loom larger. One patient with a previously recorded CR has since progressed 7.9 months after treatment, Affimed said Sunday, and four with partial responses also saw their cancers worsen after roughly three months each. On the flip side, Affimed also saw two patients maintain their complete responses beyond the 10-month mark.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.